医学
安慰剂
临床终点
内科学
溃疡性结肠炎
胃肠病学
临床试验
外科
病理
替代医学
疾病
作者
Laurent Peyrin‐Biroulet,Jessica R. Allegretti,David T. Rubin,Brian Bressler,Matthew Germinaro,Kuan-Hsiang Gary Huang,Nicole Shipitofsky,Hongyan Zhang,Rebbecca Wilson,Chenglong Han,Brian G. Feagan,William J. Sandborn,Julián Panés,Tadakazu Hisamatsu,Gary R. Lichtenstein,Bruce E. Sands,Axel Dignaß,О. Аbrahamovych,Halyna Afanasieva,Lilia Aitova
出处
期刊：Gastroenterology
[Elsevier BV]
日期：2023-09-01
卷期号：165 (6): 1443-1457
被引量：63
标识
DOI：10.1053/j.gastro.2023.08.038
摘要
The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, and/or advanced therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
Criminology34
嘻嘻哈哈
zcl
GingerF
sissiarno
昏睡的蟠桃
lalala
七月流火
BowieHuang
浮游
修仙中
cc
遇上就这样吧
MchemG
wlscj
小蜻蜓
青蛙打不过小熊
小青椒
沉心静气搞学习
归尘
shi hui
不倦
eric888
镓氧锌钇铀
star
山野有雾都
GPTea
风清扬
皖公网安备34019202002308
